* Abeona Therapeutics Inc ABEO.OQ reported a quarterly
adjusted
loss of 26 cents per share for the quarter ended in January,
higher than the same quarter last year, when the company
reported EPS of -92 cents. The mean expectation of six analysts
for the quarter was for a loss of 36 cents per share. Wall
Street expected results to range from -45 cents to -30 cents per
share.
* Reported revenue was zero; analysts expected $83.33
thousand.
* Abeona Therapeutics Inc's reported EPS for the quarter was
a
loss of 26 cents.
* The company reported a quarterly loss of $13.45 million.
* Abeona Therapeutics Inc shares had risen by 4.2% this
quarter and lost 11.8% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had risen by
about 31.3%
in the last three months.
* In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"
Wall Street's median 12-month price target for Abeona
Therapeutics Inc is $17.50
This summary was machine generated from LSEG data August 12 at
03:06 p.m. UTC. All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Jun. 30 2024 -0.36 -0.26 Beat
Mar. 31 2024 -0.51 -1.16 Missed
Dec. 31 2023 -0.47 -0.77 Missed
Sep. 30 2023 -0.53 -0.48 Beat